Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

ObjectiveThe purpose of this cost-effectiveness analysis was to estimate the effects of adding camrelizumab to standard chemotherapy as the first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) on health and economic outcomes in China.MethodsA Markov...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qilin Zhang, Pan Wu, Xucheng He, Yufeng Ding, Yamin Shu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	cost-effectiveness analysis ESCORT-1st trial esophageal squamous cell carcinoma camrelizumab first-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4a077a115a5445af8625b899a4d52b71
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4a077a115a5445af8625b899a4d52b71
record_format	dspace
spelling	oai:doaj.org-article:4a077a115a5445af8625b899a4d52b712021-12-01T22:40:45ZCost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China2234-943X10.3389/fonc.2021.790373https://doaj.org/article/4a077a115a5445af8625b899a4d52b712021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.790373/fullhttps://doaj.org/toc/2234-943XObjectiveThe purpose of this cost-effectiveness analysis was to estimate the effects of adding camrelizumab to standard chemotherapy as the first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) on health and economic outcomes in China.MethodsA Markov model was developed to simulate the clinical course of typical patients with advanced or metastatic ESCC in the ESCORT-1st trial. Weibull survival model was employed to fit the Kaplan-Meier progression-free survival and overall survival probabilities of the camrelizumab-chemotherapy and placebo-chemotherapy strategy, respectively. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICER) were estimated over a 5-year lifetime horizon. Meanwhile, one-way and probabilistic sensitivity analyses were conducted to test the uncertainty in the model.ResultsOn baseline analysis, the incremental effectiveness and cost of camrelizumab-chemotherapy versus placebo-chemotherapy were 0.15 QALYs and $7,110.56, resulting in an ICER of $46,671.10/QALY, higher than the willingness-to-pay (WTP) threshold of China ($31,498.70/QALY). The results were sensitive to the utility of PFS and cost of camrelizumab.ConclusionThe findings from the present analysis suggest that the addition of camrelizumab to chemotherapy might not be cost-effective in patients with advanced or metastatic ESCC in China.Qilin ZhangPan WuXucheng HeYufeng DingYamin ShuFrontiers Media S.A.articlecost-effectiveness analysisESCORT-1st trialesophageal squamous cell carcinomacamrelizumabfirst-line treatmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cost-effectiveness analysis ESCORT-1st trial esophageal squamous cell carcinoma camrelizumab first-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cost-effectiveness analysis ESCORT-1st trial esophageal squamous cell carcinoma camrelizumab first-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Qilin Zhang Pan Wu Xucheng He Yufeng Ding Yamin Shu Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
description	ObjectiveThe purpose of this cost-effectiveness analysis was to estimate the effects of adding camrelizumab to standard chemotherapy as the first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) on health and economic outcomes in China.MethodsA Markov model was developed to simulate the clinical course of typical patients with advanced or metastatic ESCC in the ESCORT-1st trial. Weibull survival model was employed to fit the Kaplan-Meier progression-free survival and overall survival probabilities of the camrelizumab-chemotherapy and placebo-chemotherapy strategy, respectively. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICER) were estimated over a 5-year lifetime horizon. Meanwhile, one-way and probabilistic sensitivity analyses were conducted to test the uncertainty in the model.ResultsOn baseline analysis, the incremental effectiveness and cost of camrelizumab-chemotherapy versus placebo-chemotherapy were 0.15 QALYs and $7,110.56, resulting in an ICER of $46,671.10/QALY, higher than the willingness-to-pay (WTP) threshold of China ($31,498.70/QALY). The results were sensitive to the utility of PFS and cost of camrelizumab.ConclusionThe findings from the present analysis suggest that the addition of camrelizumab to chemotherapy might not be cost-effective in patients with advanced or metastatic ESCC in China.
format	article
author	Qilin Zhang Pan Wu Xucheng He Yufeng Ding Yamin Shu
author_facet	Qilin Zhang Pan Wu Xucheng He Yufeng Ding Yamin Shu
author_sort	Qilin Zhang
title	Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
title_short	Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
title_full	Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
title_fullStr	Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
title_full_unstemmed	Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
title_sort	cost-effectiveness analysis of camrelizumab vs. placebo added to chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma in china
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/4a077a115a5445af8625b899a4d52b71
work_keys_str_mv	AT qilinzhang costeffectivenessanalysisofcamrelizumabvsplaceboaddedtochemotherapyasfirstlinetherapyforadvancedormetastaticesophagealsquamouscellcarcinomainchina AT panwu costeffectivenessanalysisofcamrelizumabvsplaceboaddedtochemotherapyasfirstlinetherapyforadvancedormetastaticesophagealsquamouscellcarcinomainchina AT xuchenghe costeffectivenessanalysisofcamrelizumabvsplaceboaddedtochemotherapyasfirstlinetherapyforadvancedormetastaticesophagealsquamouscellcarcinomainchina AT yufengding costeffectivenessanalysisofcamrelizumabvsplaceboaddedtochemotherapyasfirstlinetherapyforadvancedormetastaticesophagealsquamouscellcarcinomainchina AT yaminshu costeffectivenessanalysisofcamrelizumabvsplaceboaddedtochemotherapyasfirstlinetherapyforadvancedormetastaticesophagealsquamouscellcarcinomainchina
_version_	1718404037557092352

Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

Ejemplares similares